

Letter to editor

Accuracy of Positron Emission Tomography-Computed Tomography in Bone Marrow Involvement Lymphoma

Dear Editor,

Spread of lymphoma should be determined before treatment modality. Bone marrow involvement is an important part of staging of lymphoma. Recently the most commonly used imaging modality in lymphoma is positron emission tomography-computed tomography (PET-CT). Glucose metabolic activity is high in most lymphoma and we can evaluate spread of lymphoma with PET-CT because of its high uptake of fluorodeoxyglucose.^[1] Nowadays bone marrow biopsy and PET-CT is used routinely in order to staging of lymphoma.^[2]

We aimed to test PET-CT in bone marrow involvement lymphoma. We included 15 lymphoma patients in our study, and all patients underwent bone marrow biopsy. PET-CT was applied all patients. 10 out of 15 (66.6%) patients showed positive PET-CT results. Positive pathological biopsy material were found in eight out of 15 patients (53.3%). 40% of PET-CT findings proved true positive, 26.6% were found to be false positive. 20% proved true negative and 13.3% false negative. This results in a specificity of 42.8% and a sensitivity of 75%.

Comparison of bone marrow biopsy and PET-CT for bone marrow involvement of lymphoma

| | Bone marrow positive patients with biopsy | Bone marrow negative patients with biopsy |
|---|---|---|
| Bone marrow positive patients with PET-CT | 6 patients | 4 patients |
| Bone marrow negative patients with PET-CT | 2 patients | 3 patients |
| Total | 8 patients | 7 patients |

PET-CT: Positron emission tomography-computed tomography

Here we wanted to emphasis our experience of PET-CT in lymphoma.

Yours sincerely sir

Demet Çekdemir, Serdar Olt¹, Hasan Ergenç², Ali Tamer²

Department of Hematology, Kocaeli Acibadem Hospital, Kocaeli, ¹Department of Internal Medicine, Bitlis Mutki State Hospital, Bitlis, ²Department of Internal Medicine, Sakarya University Medical Faculty, Sakarya, Turkey

References

1. Chavdarova LI, Tzonevska AD, Piperkova EN. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI. *Hell J Nucl Med* 2013;16:223-9.
2. Jhanwar YS, Straus DJ. The role of PET in lymphoma. *J Nucl Med* 2006;47:1326-34.

Access this article online

Quick Response Code:



Website:
www.wjnm.org

DOI:
10.4103/1450-1147.150564

Address for correspondence:

Dr. Serdar Olt, Department of Internal Medicine, Bitlis Mutki State Hospital, Bitlis, Turkey. E-mail: serdarolt84@yahoo.com